Guardant Health’s Guardant360 CDx Receives FDA Approval for Camizestrant Companion Diagnostic in Advanced Breast Cancer
Guardant Health, a precision oncology company focused on advancing cancer detection and treatment through genomic testing, announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant). The approval is designed to identify patients with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer whose tumors carry ESR1 mutations before radiographic disease progression and who may benefit from treatment with camizestrant.
The regulatory decision represents an important development in the use of liquid biopsy for breast cancer management. Guardant360 CDx becomes the first FDA-approved liquid biopsy companion diagnostic specifically indicated for longitudinal testing in breast cancer. Rather than waiting for conventional imaging to demonstrate disease progression, the approach enables clinicians to monitor circulating tumor DNA (ctDNA) over time and identify emerging resistance mutations earlier.
This strategy could help move advanced breast cancer management toward a more proactive model in which treatment decisions are informed by molecular changes occurring within a tumor before those changes become visible through radiographic imaging.
The approval is supported by findings from the pivotal SERENA-6 clinical trial, which evaluated a treatment strategy based on regular ctDNA monitoring. The study investigated whether detecting newly emerging ESR1 mutations before radiographic progression and adapting therapy at that point could improve patient outcomes.
FDA Approval Marks a Shift in Breast Cancer Monitoring
Advanced HR-positive, HER2-negative breast cancer is frequently treated with endocrine therapies, including aromatase inhibitors, often in combination with cyclin-dependent kinase (CDK) 4/6 inhibitors. While these treatments can provide meaningful disease control, tumors can develop resistance over time.
One important mechanism of acquired endocrine resistance involves mutations in the estrogen receptor 1, or ESR1, gene. These mutations can alter the estrogen receptor and reduce the effectiveness of certain endocrine treatments.
Traditionally, treatment changes have often been made after a patient experiences clinical or radiographic evidence of disease progression. Imaging techniques such as CT scans and other radiographic assessments remain important tools for monitoring cancer. However, molecular changes associated with treatment resistance can occur before they are detectable through imaging.
The SERENA-6 approach seeks to close that gap.By using a liquid biopsy to periodically analyze ctDNA in the bloodstream, physicians can potentially identify the emergence of ESR1 mutations while a patient is still receiving first-line endocrine therapy and before radiographic progression has occurred. Once an actionable mutation is detected, therapy can be changed earlier.
Guardant Health said this represents a move from a reactive treatment model toward adaptive cancer management, where molecular surveillance can inform intervention before conventional measures show that the disease has progressed.
SERENA-6 Provides Clinical Evidence for Earlier Intervention
The FDA approval is based on data from the pivotal SERENA-6 trial, which introduced a treatment strategy centered on ctDNA surveillance.In the trial, patients with HR-positive, HER2-negative advanced breast cancer received an aromatase inhibitor in combination with a CDK4/6 inhibitor. Participants underwent serial ctDNA testing approximately every three months.
The goal was to identify the emergence of ESR1 mutations while patients remained free of radiographic disease progression.When an eligible patient developed an ESR1 mutation, treatment was adapted by switching the endocrine component to camizestrant while continuing the CDK4/6 inhibitor. This was compared with continuing the existing aromatase inhibitor and CDK4/6 inhibitor regimen.
The results demonstrated a significant clinical benefit associated with the ctDNA-guided treatment strategy. Patients who switched to camizestrant following detection of an ESR1 mutation experienced a 56% reduction in the risk of disease progression or death compared with those who continued the aromatase inhibitor-based regimen.The study also reported a median progression-free survival of 16.0 months compared with 9.2 months for the comparator group. According to the company, this represented a 74% longer median progression-free survival.
These findings provide clinical evidence supporting the concept that detecting molecular resistance before radiographic progression can create an opportunity to intervene earlier.
Liquid Biopsy Becomes Central to Longitudinal Monitoring
Guardant360 CDx is a blood-based genomic testing platform designed to detect clinically relevant genomic alterations using circulating tumor DNA. Because the test uses a blood sample rather than requiring tissue obtained through an invasive biopsy, liquid biopsy can offer a practical approach for repeated molecular monitoring.
The FDA’s approval for longitudinal use in breast cancer is particularly significant because repeated testing is central to the SERENA-6 treatment strategy.Instead of performing a single biomarker assessment at diagnosis or after progression, patients can undergo serial testing to monitor how the molecular characteristics of their cancer change during treatment.
This creates the potential for clinicians to obtain an ongoing picture of tumor biology. As cancer cells evolve under therapeutic pressure, new mutations may emerge. Detecting these alterations can provide information that may help physicians determine whether a treatment remains appropriate or whether another therapeutic strategy should be considered.
For patients with advanced disease, where treatment may continue across multiple lines of therapy, this type of molecular surveillance could become increasingly important.
Potential Impact on Quality of Life
The clinical significance of the SERENA-6 findings extends beyond progression-free survival.According to the reported trial data, patients managed under the ctDNA-guided treatment strategy also experienced a 47% reduction in the risk of deterioration in global health status and quality of life.
Maintaining quality of life is a major consideration in advanced cancer treatment. Patients may face prolonged treatment courses, multiple lines of therapy, adverse effects and the physical and emotional challenges associated with living with metastatic disease.An approach that can delay disease progression while helping preserve health status and quality of life could therefore have meaningful implications for patients and their care teams.
The ability to identify resistance earlier may also provide physicians with an opportunity to make treatment decisions at a time when patients have not yet experienced visible disease progression or substantial clinical deterioration.
Collaboration Between Guardant Health and AstraZeneca
The approval is also the latest outcome of a multi-year collaboration between Guardant Health and AstraZeneca.The companies have worked together to incorporate Guardant Health’s genomic testing capabilities into clinical development programs, with the Guardant360 CDx platform supporting biomarker identification and monitoring in the SERENA-6 study.
Guardant Health’s platform was used for serial testing to detect ESR1 mutations with high sensitivity. The repeated testing approach was an important component of the trial because the therapeutic decision depended on identifying emerging mutations before radiographic progression.
The collaboration highlights the growing role of companion diagnostics in precision medicine. As targeted and biomarker-driven therapies become more sophisticated, diagnostic technologies are increasingly being used not only to determine which patients may initially benefit from a therapy but also to monitor changes that could influence treatment decisions over time.
The latest approval illustrates how pharmaceutical development and diagnostic innovation can work together to create treatment strategies that depend on both a therapeutic product and a molecular testing platform.
Addressing a Significant Patient Population
Guardant Health estimates that approximately 37,000 women in the United States living with advanced HR-positive breast cancer and being treated with an aromatase inhibitor could potentially benefit from the new treatment approach.
The potential population underscores the broader significance of the FDA decision. HR-positive, HER2-negative breast cancer represents a large segment of advanced breast cancer cases, and endocrine therapy remains an important component of treatment.
For eligible patients, the ability to monitor ESR1 mutations before radiographic progression could provide a new mechanism for determining when a change in endocrine therapy may be appropriate.
The approach also reflects the increasing importance of molecular monitoring in cancer care. As genomic testing becomes more integrated into clinical workflows, biomarkers can potentially provide information between conventional imaging assessments and help clinicians understand disease evolution more closely.
Expanding the Clinical Utility of Guardant360 CDx
The FDA decision marks the 29th companion diagnostic indication for Guardant360 CDx across multiple tumor types globally, according to Guardant Health.The company has positioned the platform as a broadly applicable tool for precision oncology, with applications spanning multiple cancer types and therapeutic decisions.
The platform’s expanding clinical use is also supported by coverage from Medicare and commercial payers, representing more than 300 million covered lives, according to the company.Broader payer coverage can be an important consideration when diagnostic technologies move from clinical trials into routine medical practice. Accessibility to testing can influence whether physicians are able to incorporate molecular information into treatment decisions across diverse patient populations.
A New Model for Adaptive Cancer Management
Helmy Eltoukhy, chairman and co-CEO of Guardant Health, described the FDA approval as a landmark development in defining how disease progression can be monitored.The company’s perspective is that the SERENA-6 paradigm represents more than an additional diagnostic indication. It demonstrates a potentially broader model for managing cancer in which molecular signals are detected and acted upon before conventional imaging confirms progression.
This distinction is important.Radiographic progression remains a fundamental measure in oncology, but cancer biology does not necessarily change at the same pace as what can be observed on a scan. Molecular resistance can emerge earlier, creating a potential window for intervention.
Liquid biopsy offers one way to monitor this molecular evolution through minimally invasive blood testing.If similar strategies prove successful in other cancers and therapeutic settings, ctDNA surveillance could become a more common component of adaptive treatment planning.
Implications for the Future of Precision Oncology
The Guardant360 CDx approval arrives as precision oncology continues to evolve beyond one-time biomarker testing.Earlier generations of precision medicine often focused on identifying a molecular alteration at diagnosis and matching patients with a corresponding therapy. The emerging model is more dynamic, recognizing that tumors can change substantially during treatment.
Longitudinal liquid biopsy testing could help clinicians track those changes and potentially adapt treatment accordingly.For advanced breast cancer, the SERENA-6 findings provide a concrete example of how this strategy can be incorporated into clinical care. Patients can be monitored for emerging ESR1 mutations, and an actionable molecular change can trigger a treatment decision before conventional radiographic progression becomes apparent.
The FDA approval therefore represents a significant milestone for Guardant Health, AstraZeneca and the broader precision oncology field.By combining an FDA-approved liquid biopsy companion diagnostic with a next-generation endocrine therapy, the new approach creates a framework for earlier molecular intervention in advanced breast cancer.
As cancer treatment becomes increasingly personalized, the ability to continuously monitor tumor biology may become just as important as identifying the right treatment at the beginning of therapy. The Guardant360 CDx approval demonstrates the potential of liquid biopsy to support that evolution, offering clinicians an additional way to understand how disease is changing and when treatment may need to change with it.
Source link: https://investors.guardanthealth.com/
